BioSpace News Archive

Seegene unveils world’s first commercialized ‘3 Ct’ PCR assay

Seegene Inc. announced the development of the world’s first commercialized PCR assay applying ‘3 Ct’ technology.

April 26, 2022
·
3 min read
Biotech Beach

NuVasive Specialized Orthopedics Surpasses 100 Peer-Reviewed Publications of the Precice System for Limb Lengthening

NuVasive, Inc. announced a milestone of more than 100 peer-reviewed publications of the Precice® System for conditions related to limb lengthening and reconstruction from NuVasive Specialized Orthopedics™.

April 26, 2022
·
4 min read
Genetown

Zambon to present data on lung transplantation trends and survival rates in Europe at ISHLT 2022

Zambon is presenting two posters at the International Society for Heart and Lung Transplantation (ISHLT) Annual 2022 Meeting taking place April 27–30 in Boston, MA.

April 26, 2022
·
4 min read
Business

Rapid Dose Therapeutics and Skycare Compounding Labs to Provide Patients with a Novel Oral Delivery Option for Pharmaceutical Products

Rapid Dose Therapeutics Corp. and Skycare Compounding Labs today announce the signing of a mutually-beneficial Managed Strip Services Agreement for the production of oral thin film strips of approved pharmaceuticals.

April 26, 2022
·
4 min read
FDA

Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201

Gamida Cell Ltd. today announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application and removed the clinical hold for a cryopreserved formulation of GDA-201.

April 26, 2022
·
6 min read
Lone Star Bio

Natera Announces Definitive Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease (CKD)

Natera, Inc. today announced the RenaCARE (Renasight Clinical Application, Review and Evaluation) study - a real world, prospective, multi-center clinical study to assess the clinical utility of the Renasight™ genetic testing panel.

April 26, 2022
·
5 min read
Drug Development

Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in the Phase 2 GATEWAY clinical study of investigational ARO-ANG3 for the treatment of patients with homozygous familial hypercholesterolemia (HoFH).

April 26, 2022
·
4 min read
Business

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

Galmed Pharmaceuticals Ltd. announced today that it will host a conference call and webcast on Monday, May 2, 2022, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the fourth quarter and year ended December 31, 2021.

April 26, 2022
·
2 min read
TC BioPharm to Participate in Upcoming Conferences

TC Biopharm PLC, a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced that the company will be participating in several upcoming conferences.

April 26, 2022
·
3 min read
Drug Development

Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma

Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis’ ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy and safety of Evaxion’s personalized cancer immunotherapy EVX-01.

April 26, 2022
·
4 min read